Masahisa Hijikata, MD in East Lynn, MA - Urology

Masahisa Hijikata, MD is a Urology physician based in East Lynn, Massachusetts. Masahisa Hijikata is licensed to practice in Massachusetts (license number 38557) and his current practice location is 225 Boston St, East Lynn, Massachusetts. He can be reached at his office (for appointments etc.) via phone at (781) 595-3507.

NPI number for Masahisa Hijikata is 1831232313 and his current mailing address is 225 Boston St, Lynn, Massachusetts. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1831232313.

Contact Information

	Masahisa Hijikata, MD
	225 Boston St, East Lynn, MA 01904-3137
	(781) 595-3507
	Not Available

Physician's Profile

Full Name	Masahisa Hijikata
Gender	Male
Speciality	Urology
Location	225 Boston St, East Lynn, Massachusetts
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1831232313
Provider Enumeration Date: 02/15/2007
Last Update Date: 12/04/2007

Medical Identifiers

Medical identifiers for Masahisa Hijikata such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1831232313	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	38557 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Masahisa Hijikata is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Masahisa Hijikata, MD 225 Boston St, Lynn, MA 01904-3137 Ph: (781) 595-3507	Masahisa Hijikata, MD 225 Boston St, East Lynn, MA 01904-3137 Ph: (781) 595-3507

News Archive

ABTC receives NCCA accreditation for three transplant certification examinations

Three certification examinations of the American Board for Transplant Certification (ABTC) are now accredited by the National Commission for Certifying Agencies.

FDA approves antibacterial drug to treat travelers' diarrhea

The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

Edixomed develops revolutionary technology for tackling antimicrobial resistance

New results announced at the recent Wounds UK conference and Eurobiofilms 2017 congress, have provided the latest evidence that Edixomed, a UK biotechnology company, has developed a revolutionary new technology for tackling the enormous public health challenge of antimicrobial resistance (AMR).

Lonza launches new website to support bioresearch, drug discovery scientists

Lonza Bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com. Filled with detailed application and product information, the website has been designed to support the work of scientists across the bioresearch, drug discovery and pharmaceutical manufacturing fields.

Masahisa Hijikata, MD - Urology in East Lynn, MA